Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Accumulated Depreciation & Amortization (2016 - 2025)

Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $6.0 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 25.0% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, up 25.0%, while the annual FY2025 figure was $22.2 million, 31.36% up from the prior year.
  • Accumulated Depreciation & Amortization reached $6.0 million in Q4 2025 per ARWR's latest filing, down from $22.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $22.2 million in Q3 2025 to a low of $1.5 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $6.3 million, with a median of $4.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 306.25% in 2022, then crashed 55.38% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $2.1 million in 2021, then increased by 9.52% to $2.3 million in 2022, then surged by 65.22% to $3.8 million in 2023, then increased by 26.32% to $4.8 million in 2024, then increased by 25.0% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Accumulated Depreciation & Amortization are $6.0 million (Q4 2025), $22.2 million (Q3 2025), and $5.8 million (Q2 2025).